Future prospects of nanoparticles on brain targeted drug delivery

Chakraborty, Chiranjib; Sarkar, Biplab; Hsu, Chen-Pin; Wen, Zhi‐Hong; Lin, Chan-Shing; Shieh, Po Chuen

doi:10.1007/s11060-008-9759-2

Cited by 43 publications

(25 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…BBB represents an insurmountable obstacle for a large number of drugs including antibiotics, antineoplastic agents and various CNS-active drugs like neuropeptides. This creates a considerable threat for the therapy of cerebral diseases (Chakraborty et al, 2009). It is increasingly clear that crossing of BBB and drug delivery to CNS is a complex and challenging task requiring close collaboration and common efforts among researchers of several scientific areas including pharmaceutical sciences, biological chemistry, physiology and pharmacology (Denora et al, 2009).…”

Section: Experimental Factors Considered While Delivering Drug For Inmentioning

confidence: 99%

Insights into direct nose to brain delivery: current status and future perspective

et al. 2013

View full text Add to dashboard Cite

Now a day's intranasal (i.n) drug delivery is emerging as a reliable method to bypass the bloodbrain barrier (BBB) and deliver a wide range of therapeutic agents including both small and large molecules, growth factors, viral vectors and even stem cells to the brain and has shown therapeutic effects in both animals and humans. This route involves the olfactory or trigeminal nerve systems which initiate in the brain and terminate in the nasal cavity at the olfactory neuroepithelium or respiratory epithelium. They are the only externally exposed portions of the central nervous system (CNS) and therefore represent the most direct method of noninvasive entry into the brain. This approach has been primarily used to explore therapeutic avenues for neurological diseases. The potential for treatment possibilities with olfactory transfer of drugs will increase as more effective formulations and delivery devices are developed. Recently, the apomorphine hydrochloride dry powders have been developed for i.n. delivery (Apomorphine nasal, Lyonase technology, Britannia Pharmaceuticals, Surrey, UK). The results of clinical trial Phase III suggested that the prepared formulation had clinical effect equivalent to subcutaneously administered apomorphine. In coming years, intranasal delivery of drugs will demand more complex and automated delivery devices to ensure accurate and repeatable dosing. Thus, new efforts are needed to make this noninvasive route of delivery more efficient and popular, and it is also predicted that in future a range of intranasal products will be used in diagnosis as well as treatment of CNS diseases. This review will embark the existing evidence of nose-to-brain transport. It also provides insights into the most relevant pre-clinical studies of direct nose-brain delivery and delivery devices which will provide relative success of intranasal delivery system. We have, herein, outlined the relevant aspects of CNS drugs given intranasally to direct the brain in treating CNS disorders like Alzheimer's disease, depression, migraine, schizophrenia, etc.

show abstract

Section: Experimental Factors Considered While Delivering Drug For Inmentioning

confidence: 99%

Insights into direct nose to brain delivery: current status and future perspective

et al. 2013

View full text Add to dashboard Cite

show abstract

“…[112][113][114][115][116] Major specific applications of biocompatible NPs have been in tumor targeting using monoclonal antibodies or folate moieties covalently bound to the NP, 117,118 oral drug delivery exploring the protective effect of NPs against degradation by digestive enzymes and their systemic dissemination, 116,119,120 vaccine and gene delivery due to NPs rapid uptake by cells followed by NPs escape from degradation in the endosomes and cargo release to the cytoplasm 121,122 and drug delivery to the brain due to the ability of certain NPs to cross the BBB. [123][124][125][126] Drugs that are normally unable to cross the BBB following i.v. injection can be transported across this barrier by binding to poly(butyl cyanoacrylate) NPs coated with polysorbate 80.…”

Section: Nanomedicines Based On Biocompatible Polymersmentioning

confidence: 99%

Biomimetic Systems in Nanomedicine

Carmona-Ribeiro¹

2014

Frontiers in Nanobiomedical Research

View full text Add to dashboard Cite

Mimicking Nature has been a major source of inspiration for producing novel pharmaceutical formulations with improved therapeutic index and reduced toxicity. In Nature, the self-assembly of biomolecules driven by intermolecular interactions leads to highly functional, nanosized biological machines. Novel directions for drug and vaccine delivery to cure or prevent disease somehow have to copy Mother Nature wisdom. In this chapter, smart nanocarriers produced from the self-assembly of biocompatible polymers, lipids or hybrid nanoparticles (NPs) are presented and some of their applications in antimicrobial chemotherapy, drug and vaccine delivery discussed. Self-Assembly and Intermolecular InteractionsWeak intermolecular interactions are important for the rational design of novel biomimetic materials. Main weak interactions are the van der Waals interaction (ion-dipole, dipole-dipole, dipole-induced dipole interactions, induced-dipole induced-dipole), the electrostatic interaction, the hydrogen bonds, the hydrophobic interactions and the steric repulsion. 1,2 The weak but cooperative hydrogen bonding between the two strands of double-stranded DNA is a wise approach used by Nature to keep the strands together without hampering replication and transcription. 3 The repulsion between nonpolar Handbook of Nanobiomedical Research Downloaded from www.worldscientific.com by UNIVERSITY OF BIRMINGHAM LIBRARY -INFORMATION SERVICES on 03/21/15. For personal use only.

show abstract

“…This limit is confirmed by a number of publications (see review [9]) highlighting that the percentage of NPs lying in the capillary endothelial cells is much greater than that lying inside the CNS parenchyma. Moreover, another possible limitation of receptor-mediated endocytosis is the possible saturation mechanisms due to endogenous ligands bound to the receptor, thus hampering the efficiency of receptor-mediated endocytosis [10][11][12][13][14][15][16][17].…”

Section: "If 'Personalized Medicine' Is a Way Tomentioning

confidence: 99%